Number Of Cancer Deaths Research Articles

Reducing Alcohol Use to Prevent Cancer Deaths: Estimated Effects Among U.S. Adults

The Dietary Guidelines for Americans, 2020-2025 recommends non-drinking or no more than 2 drinks for men or 1 drink for women in a day. However, even at lower levels, alcohol use increases the risk for certain cancers. This study estimated mean annual alcohol-attributable cancer deaths and the number of cancer deaths that could potentially be prevented if all U.S. adults who drank in excess of the Dietary Guidelines had instead consumed alcohol to correspond with typical consumption of those who drink within the recommended limits. Among U.S. residents aged ≥20 years, mean annual alcohol-attributable cancer deaths during 2020-2021 that could have been prevented with hypothetical reductions in alcohol use were estimated. Mean daily alcohol consumption prevalence estimates from the 2020-2021 Behavioral Risk Factor Surveillance System, adjusted to per capita alcohol sales to address underreporting of drinking, were applied to relative risks to calculate population-attributable fractions for cancers that can occur from drinking alcohol. Analyses were conducted during February-April 2023. In the U.S., an estimated 20,216 cancer deaths were alcohol-attributable/year during 2020-2021 (men: 14,562 [72.0%]; women: 5,654 [28.0%]). Approximately 16,800 deaths (83% of alcohol-attributable cancer deaths, 2.8% of all cancer deaths) could have been prevented/year if adults who drank alcohol in excess of the Dietary Guidelines had instead reduced their consumption to ≤2 drinks/day for men or ≤1 drink/day for women. Approximately 650 additional deaths could have been prevented annually if men consumed 1 drink/day, instead of 2. Implementing evidence-based alcohol policies (e.g., increasing alcohol taxes, regulating alcohol outlet density) to decrease drinking could reduce alcohol-attributable cancers, complementing clinical interventions.

A cross-cultural analysis of the relationship between the level of depression and attitudes toward death in cancer patients

Introduction♦Over the last 10 years, the number of cancer patients in the world has increased by almost 23%, and the number of cancer deaths has also increased by about 10%. Malignant neoplasms still remain as one of the main causes of mortality in the population. Patients with oncopathology are characterized by a high level of depression which leads to inadequate attitudes towards the disease and its treatment, and this may further act as a risk factor for disease susceptibility and aggravate its course (Schulz-Kindermann, 2021). It is relevant to search for variables that act as a personal resource in coping with cancer. It is hypothesized that one such personal resource is the specificity of attitudes towards death.ObjectivesTo conduct a comparative analysis of the relationship between the level of depression and the peculiarities of the attitude to death in cancer patients in Russia and Germany.Methods▪Beck Depression Inventory to determine the level of depression severity.▪Death Attitude Profile-Revised to determine the type of attitude to death.For statistical processing of data, the SPSS 23.0 statistical package was used with a preliminary check for normality of distribution using the Kolmogorov-Smirnov statistical criterion.SELECTIONThe sample consisted of a total number of 50 cancer patients with 25 each undergoing treatment in Russia (Moscow) and in Germany (Munich). The study was based on the sample obtained from the P. A. Herzen Moscow Research Oncological Institute and the Helios Munich-West Clinic. Overall, the sample was relatively gender-balanced.ResultsThe following results were obtained from the study: 1.The mean value of depression level in cancer patients is higher in Russia than in Germany.2.The level of depression in cancer patients in both the countries is correlated with:▪marital status (p=0.36)▪stage of disease (p=0.001)▪type of treatment (p=0.001)▪belief in God (p=0.024)▪adherence to a particular religious denomination (p=0.008)3.The level of depression was correlated with a certain type of attitude towards death: a higher level of depression was associated with scores on the “fear of death” scale (p=0.000), and a lower level (or lack of ) with the “neutral acceptance of death” scale (p=0.000)4.The fear of death is seen to be most common in the sample of patients from Russia, while the neutral acceptance of death is more prevalent in the sample from Germany.ConclusionsThe results suggest that a positive attitude to death (neutral as one of these types) is correlated, along with other factors, with lower levels of depression, which may be a personal resource in coping with the disease.This allows us to make the assumption that when providing psychological support to cancer patients, it is necessary to pay attention not only to the attitude to life and illness, but also to the attitude to death.Disclosure of InterestNone Declared

Factors related to depression in non-small-cell lung cancer patients treated at K Hospital during 2021 - 2022

Non-small cell lung cancer is currently the second most common cancer when assessing common cancer and the number of cancer deaths; there are a limited number of studies about depression in lung cancer patients in Vietnam. This cross -sectional descriptive study aimed to describe depression in non-small cell lung cancer patients treated at K Hospital from 2021 – 2022 and associated factors. The study was conducted on 243 NSCLC patients treated at K Tan Trieu Hospital by direct phone call interview and psychiatric clinical examination. We applied the PHQ-9 scale and DSM-5 for screening and confirmed depression, and the SF-12 scale was applied for quality of life measurement. The study found that stage IV disease increased the risk of depression more than 6 times in lung cancer patients (OR = 6.47; p<0.05) and patients with poor QoL in the depression group, in which quality of life of mental health (36.94 ± 5.43) and physical health (41.78 ± 7.17) were all lower than those in the group without depression. Measures to monitor mental health, screen for early detection and treatment interventions, and improve quality of life are the top priorities to reduce the risk of depression in patients with non-small cell lung cancer.

Deaths averted: An unbiased alternative to rate ratios for measuring the performance of cancer screening programs.

Screening trials and meta-analyses emphasize the ratio of cancer death rates in screening and control arms. However, this measure is diluted by the inclusion of deaths from cancers that only became detectable after the end of active screening. We review traditional analysis of cancer screening trials and show that ratio estimates are inevitably biased to the null, because follow-up (FU) must continue beyond the end of the screening period and thus includes cases only becoming detectable after screening ends. But because such cases are expected to occur in equal numbers in the two arms, calculation of the difference between the number of cancer deaths in the screening and control arms avoids this dilutional bias. This difference can be set against the number of invitations to screening; we illustrate by reanalyzing data from all trials of tomography screening of lung cancer (LC) using this measure. In nine trials of LC screening from 2000 to 2013, a total of 94,441 high-risk patients were invited to be in screening or control groups, with high participation rates (average 95%). In the older trials comparing computed tomography to chest X-ray, 88,285 invitations averted 83 deaths (1068 per death averted (DA)). In the six more recent trials with no screening in the control group, 69,976 invitations averted 121 deaths (577 invitations per DA). Screens per DA is an undiluted measure of screening's effect and it is unperturbed by the arbitrary duration of FU. This estimate can be useful for program planning and informed consent.

Dietary consumption trend and its correlation with global cancer burden: A quantitative and comprehensive analysis from 1990 to 2019

ObjectiveThe aim of this study was to estimate the effect of dietary consumption on cancer burden and formulate an effective solution. MethodsDietary consumption, number of cancer deaths, disability-adjusted life years, and corresponding age-standardized rates were extracted from the Global Burden of Disease Study 2019. The annual percentage change was used to quantify the temporal trends in cancer burden and dietary consumption. Age, sex, location, and sociodemographic index were stratified to further analyze the discrepancy in cancer burden attributable to dietary intake. ResultsFive cancers (breast, colon and rectal, tracheal, bronchus and lung, esophageal, and stomach) were documented to be associated with dietary consumption in the Global Burden of Disease database. The age-standardized death rate and age-standardized disability-adjusted life years rate in 2019 were 7.56 and 1168.77 per 100 000 population, respectively. For most cancers, the age-standardized death rate and age-standardized disability-adjusted life years rate displayed a decreasing tendency, with annual percentage change varying from –3.60 to –0.29 and from –3.64 to –0.03 from 1990 to 2019, respectively. The age-standardized death rate and age-standardized standardized disability-adjusted life years rate were higher in men than in women (9.68 vs 5.79 and 213.16 vs 129.18, respectively). In addition, the diet-related cancer burden in higher sociodemographic index regions exceeded that in lower sociodemographic index regions. ConclusionDietary consumption has a considerable influence on cancer burden, among which colon and rectal cancer burden account for the largest proportion. Increasing the intake of whole grains, milk, fiber, calcium, vegetables, and fruits and reducing the consumption of processed meat and sodium are instrumental in lowering the disease burden of cancer. The quantitative analysis of dietary consumption would provide a more detailed reference for diet-related decision makers and raise awareness of healthy dietary habits in diet management departments, food production enterprises, and the general public.

Some Factors Related to Depression in Non-Small-Cell Lung Cancer Patients Treated at K Hospital During 2021 – 2022

Background Understanding lung cancer is currently the second most common cancer when assessing common cancer and the number of cancer deaths; there are a limited number of studies about depression in lung cancer patients in Vietnam. Objective This study aimed to describe depression in non-small cell lung cancer patients treated at K Hospital from 2021 – 2022 and associated factors. Methods Cross-sectional descriptive study. The study was conducted on 243 NSCLC patients treated at K Tan Trieu Hospital by direct phone call interview and psychiatric clinical examination. We applied the PHQ-9 scale and DSM-5 for screening and confirmed depression, and the SF-12 scale was applied for quality of life measurement. Results The study found that the risk factors related to depression included stage IV disease increasing the risk of depression more than 6 times in lung cancer patients (OR = 6.47; p<0.05) and patients with poor QoL in the depression group, in which quality of life of mental health (36.94 ± 5.43) and physical health (41.78 ± 7.17) were all lower than those in the group without depression. Conclusions Measures to monitor mental health, screen for early detection and treatment interventions, and improve quality of life are the top priorities to reduce the risk of depression in patients with non-small cell lung cancer.

Bacteriophage Therapy as an Alternative to Antibiotics: A Dead End or A Solution?

Antibiotic resistance has been around for years and could lead to a serious crisis in the near future. If the problem of antibiotic resistance is not solved, antimicrobial resistance is predicted to increase, killing 10 million people annually by 2050 (more than the number of cancer deaths), and costing the global economy approximately $100 trillion USD, because of this, it will need the rapid development of alternative therapies. This issue prompted scientists to find a solution; the use of bacteriophages as an alternative to antibiotics is one of these tactics. In this review article, I will first focus on bacteriophages from various aspects and then, by analyzing the available information, I will try to answer the following questions:
 
 Given the meager standard clinical data and characteristics of bacteriophages, is bacteriophage therapy a safe and reliable method?
 Given the short time left before the antibiotic resistance crisis, is it cost-effective to invest in bacteriophage?
 Are bacteriophages a double-edged sword? (Besides being used to treat bacterial diseases in the future, do bacteriophages have the potential to become a human virus in the future?)

Long-term projections of cancer incidence and mortality in Canada: The OncoSim All Cancers Model

Using the OncoSim All Cancers Model, we estimated the annual cancer incidence, mortality and cancer management costs in Canada from 2020 to 2040. Incidence for each cancer type was estimated from logistic regression analyses of the Canadian Cancer Registry (1992–2017), with province/territory, sex, five-year age groups and year as covariates. Deaths were estimated by sex and tumour site for cancers diagnosed between 2000 and 2017 (deaths to the end of 2017). The total cost of a cancer type was the sum of costs for individuals across four phases of cancer care. The projections presented in this study were generated based on a simulation of 32 million cases. The OncoSim All Cancers Model projects a 40% increase in the overall number of incident cancer cases from 2020 to 2040. The number of the four most commonly diagnosed cancers in Canada (breast, colorectal, lung, and prostate) are projected to increase annually. The overall number of cancer deaths is projected to increase by 44% from 2020 to 2040. More cancer deaths are projected in males than in females. The age-standardized mortality rate is expected to remain relatively stable over time. Overall cancer management costs are projected to increase from $20.6B in 2020 to $31.4B in 2040. Due mainly to an aging population and population growth in Canada, we estimate that cancer incidence, mortality and cancer management costs will increase considerably between 2020 and 2040. These results highlight the importance of planning for increasing investment and capacity in cancer control.

Estimation of cancer incidence in the state of São Paulo, Brazil, based on real data

This study aims to evaluate the feasibility of applying a method of estimating the incidence of cancer to regions of the state of São Paulo, Brazil, from real data (not estimated) and retrospectively comparing the results obtained with the official estimates. A method based on mortality and on the incidence to mortality (I/M) ration was used according to sex, age, and tumor location. In the I/M numerator, new cases of cancer were used from the population records of Jaú and São Paulo from 2006-2010; in the denominator, deaths from 2006-2010 in the respective areas, extracted from the national mortality system. The estimates resulted from the multiplication of I/M by the number of cancer deaths in 2010 for each region. Population data from the 2010 Demographic Census were used to estimate incidence rates. For the adjustment by age, the world standard population was used. We calculated the relative differences between the gross incidence rates estimated in this study and the official ones. Age-adjusted cancer incidence rates were 260.9/100,000 for men and 216.6/100,000 for women. Prostate cancer was the most common in males, whereas breast cancer was most common in females. Differences between the rates of this study and the official rates were 3.3% and 1.5% for each sex. The estimated incidence was compatible with the officially presented state profile, indicating that the application of real data did not alter the morbidity profile, while it did indicate different risk magnitudes. Despite the over-representativeness of the cancer registry with greater population coverage, the selected method proved feasible to point out different patterns within the state.

Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study

SummaryBackgroundLong-term projections of cancer incidence and mortality estimate the future burden of cancer in a population, and can be of great use in informing the planning of health services and the management of resources. We aimed to estimate incidence and mortality rates and numbers of new cases and deaths up until 2044 for all cancers combined and for 21 individual cancer types in Australia. We also illustrate the potential effect of treatment delays due to the COVID-19 pandemic on future colorectal cancer mortality rates.MethodsIn this statistical modelling study, cancer incidence and mortality rates in Australia from 2020 to 2044 were projected based on data up to 2017 and 2019, respectively. Cigarette smoking exposure (1945–2019), participation rates in the breast cancer screening programme (1996–2019), and prostate-specific antigen testing rates (1994–2020) were included where relevant. The baseline projection model using an age-period-cohort model or generalised linear model for each cancer type was selected based on model fit statistics and validation with pre-COVID-19 observed data. To assess the impact of treatment delays during the COVID-19 pandemic on colorectal cancer mortality, we obtained data on incidence, survival, prevalence, and cancer treatment for colorectal cancer from different authorities. The relative risks of death due to system-caused treatment delays were derived from a published systematic review. Numbers of excess colorectal cancer deaths were estimated using the relative risk of death per week of treatment delay and different durations of delay under a number of hypothetical scenarios.FindingsProjections indicate that in the absence of the COVID-19 pandemic effects, the age-standardised incidence rate for all cancers combined for males would decline over 2020–44, and for females the incidence rate would be relatively stable in Australia. The mortality rates for all cancers combined for both males and females are expected to continuously decline during 2020–44. The total number of new cases are projected to increase by 47·4% (95% uncertainty interval [UI] 35·2–61·3) for males, from 380 306 in 2015–19 to 560 744 (95% UI 514 244–613 356) in 2040–44, and by 54·4% (95% UI 40·2–70·5) for females, from 313 263 in 2015–19 to 483 527 (95% UI 439 069–534 090) in 2040–44. The number of cancer deaths are projected to increase by 36·4% (95% UI 15·3–63·9) for males, from 132 440 in 2015–19 to 180 663 (95% UI 152 719–217 126) in 2040–44, and by 36·6% (95% UI 15·8–64·1) for females, from 102 103 in 2015–19 to 139 482 (95% UI 118 186–167 527) in 2040–44, due to population ageing and growth. The example COVID-19 pandemic scenario of a 6-month health-care system disruption with 16-week treatment delays for colorectal cancer patients could result in 460 (95% UI 338–595) additional deaths and 437 (95% UI 314–570) deaths occurring earlier than expected in 2020–44.InterpretationThese projections can inform health service planning for cancer care and treatment in Australia. Despite the continuous decline in cancer mortality rates, and the decline or plateau in incidence rates, our projections suggest an overall 51% increase in the number of new cancer cases and a 36% increase in the number of cancer deaths over the 25-year projection period. This means that continued efforts to increase screening uptake and to control risk factors, including smoking exposure, obesity, physical inactivity, alcohol use, and infections, must remain public health priorities.FundingPartly funded by Cancer Council Australia.

Impact of the COVID-19 pandemic on cancer incidence and mortality

Impact of the COVID-19 pandemic on cancer incidence and mortality

CaPaBLE: Comparing the Patient Generated Index to standard quality of life measures in patients and caregivers affected by high-grade brain tumours - Preliminary analysis

Abstract Aims High grade gliomas are rare but have the highest number of cancer deaths in the under-40s. Treatment options are limited, resulting in a clinical focus on maintaining quality of life (QoL). However standard QoL assessment tools are time consuming, may not reflect an individual’s priorities, and are rarely used in clinical practice. Moreover, the impact of caring for someone with a high grade glioma is seldom assessed. An alternative approach to assessing quality of life is to use a patient - or carer-generated index (PGI/CaGI), which asks patients & carers to raise, rank and number their concerns. This may offer a route to individualised QoL assessments within clinical and research settings. The CaPaBLE study tests the feasibility and acceptability of the PGI and CaGI methodology in patients with high-grade glioma and their caregivers. This paper highlights key similarities and differences of the PGI/CaGI to standard QoL questionnaires. Method CaPABLE is an observational phase 2 non-randomised study following patients and their caregivers over 6 months starting at either first diagnosis or recurrence (https://www.isrctn.com/ISRCTN45555598). Patients and caregivers complete both standard questionnaires (EORTC QLQ C30 & BN20 and CargoQOL) and PGI/CAGI at 5 timepoints over the 6 month period. Each time the patients/caregivers complete the PGI/CAGI they are asked to identify up to 5 main topics of concern for their QoL, to score these, and rank their importance. For this analysis, we grouped topics into themes, compared the stability of themes over time and to EORTC domains. Analyses of EORTC measures are conducted using standard scoring approaches. Here we present an initial analysis of occurrence of PGI/CaGI themes compared to EORTC domains, but do not consider scores or ranking. Results 6 patients (4 male) and 5 caregivers (3 female; 4 paired with patients; one unpaired) have completed both standard questionnaire and PGI/CaGI at three or more time points, with a total of 19 (patient) and 18 (caregiver) assessments. On average people reported 3 topics at each assessment. The PGI generated 59 topics (32 themes); the CaGI, 50 topics (23 themes) and themes were consistent over time. The most common domain raised by patients was “social life” (13). Caregivers raised “personal life and family” (12 and “planning ahead” (7) more commonly. Of the 32 PGI themes, 23 align with EORTC domains. 9 PGI themes were not represented in the EORTC questionnaires, and 14 EORTC domains did not appear in the PGI. Of the 23 CaGI themes, 17 align with 7 CarGOQOL domains. 6 CaGI themes were not represented in the CarGOQOL and 3 CarGOQOL domains did not appear in the CaGI. Conclusion PGI and CaGI themes coincide with the main domains of EORTC (i.e., cognitive, social, role, physical, emotional functioning, future uncertainty). However, there were significant discrepancies: PGI (e.g., intimacy, ability to drive, and COVID related restrictions) and CaGI (e.g. personal life & family) highlighted themes that are not in the standard questionnaires. Both PGI/CaGI and standard questionnaires agree that symptom-related issues such as pain and seizures are not the main priority when it comes to QoL. In addition, CarGOQOL reports positive aspects of care, whereas CaGI only raised negative areas. This study is the first to show the feasibility of PGI/CaGI in a brain tumour patient & caregiver population. PGI/CaGI are notably quicker to complete and provide insights not captured by standard questionnaires. We are continuing to recruit patients and caregivers, and have submitted a protocol amendment to carry out qualitative interviews with patients and caregivers, to explore their views further.

A concise critique on Breast Cancer: A historical and scientific perspective

Breast cancer, the most pervasive cancer afflicting 2.1 million women worldwide, contributes to the highest number of cancer deaths in women. It can affect both genders, but it is more prevalent in women than in men. It seems to be the major unbearable global cancer burden. As a result, it creates a great impact on society. The exact etiology is still mysterious, but its associated risk factors were evidently identified. Although there are several sophisticated treatments available, continuing changes in the breast cancer prognosis culminated in more than 60 % of mortalities from this metastatic disease. Therefore, in an attempt to offer a clear picture of this enigmatic condition, this review outlines a concise summary of the breast cancer history, epidemiology, types, available treatments, genomics role, signaling pathways as well as its alternative splice variants.

Predicting the mortality of smoking attributable to cancer in Qingdao, China: A time-series analysis.

Smoking is the leading preventable cause of death and disability from cancer in China. To provide a scientific basis for tobacco control strategies and measures, this study investigated cancer deaths attributed to smoking from 2005 to 2017 and predicted mortality trends from 2018 to 2020 in Qingdao. We used time series analysis to evaluate the number of deaths attributed to smoking among residents over 35 years old in Qingdao and predicted mortality trends. The number of cancer deaths attributed to smoking in Qingdao from 2005 to 2016 was between 170 and 407, showing an upward trend and a certain periodicity. The best model is the ARIMA (2,1,0)×(3,1,0)12, with the lowest BIC (6.640) and the highest stationary R2 (0.500). The predicted cancer deaths curve attributed to smoking in 2017 is consistent with the actual curve, with an average relative error of 5.74%. Applying this model to further predict the number of cancer deaths attributed to smoking in Qingdao from January 2018 to December 2020, the predicted results were 5,249, 5,423 and 6,048, respectively. The findings emphasized the need to further strengthen tobacco control measures to reduce the burden of disease caused by tobacco.

10-Year Mortality Pattern Among Cancer Patients in Lagos State University Teaching Hospital, Ikeja, Lagos.

BackgroundGlobally, cancer is a major leading health problem with an estimated 10 million incidences and 6 million cancer deaths annually. In Nigeria, an estimated 72,000 cancer deaths occur annually, and 102,000 new cases are diagnosed from its population of 200 million people. These are, however, estimates, it is necessary to document the yearly trends and patterns of cancer mortality with regards to the different regions in the country.Methodologywe conducted this study at the Lagos State University Teaching hospital (LASUTH), Ikeja, Lagos to document mortality patterns from 2009 to 2018. Data extracted included those from the patient’s case notes, admission and death registers, and death certificates. we also had records from the hospital records department and medical wards. We then documented cancer mortality over the study period.ResultsA total number of 6,592 deaths were recorded over ten years, and 1,133 cases were cancer-related deaths. This number puts the percentage of cancer-related deaths at 17.2%. Male patients accounted for 54.0%, and female patients are 46.0%. Breast cancer accounted for the highest mortality, followed by prostate cancer. The highest number of deaths were recorded in 2010 at 821, followed by 2011 at 799, 2015 at 780, and the least in 2017 at 513. There is also a significant general increase in odds of mortality with an increase in decades of life.ConclusionThis study shows that about one in five deaths, over the last ten years, from this tertiary institution, is related to a cancer diagnosis. Even though a yearly decline in the number of cancer deaths was noticed, probably due to increased awareness and governmental intervention, the percentage still remains high.

Isolation Of Anticancer Drug Taxol Producing Endophytic Fungus Alternaria Alternata By Using HPLC And LC- MS

Abstract Introduction/Objective In the exploration of an alternative source, optimum and numerous solvents with different percentage were exploited to extract Taxol from plant palm branche. The fungal endophytes producing secondary metabolites that are effective against the human infections have fascinated many researchers across the world. Among these, the exploration for novel cancer therapeutic agents is of countless reputation due to upsurge in the number of cancer deaths, high worth of the drugs and the side effects concomitant with cancer treatments. Accordingly, in the current study, an endophytic fungal strain was isolated from its host plant palm branche and identified as Alternaria Alternata based on its morphological features and internal transcribed spacer sequence analysis. Methods Firstly, palm branche were collected for the isolation of endophytic fungi. The samples were placed on PDA plates and after 72 h, the mycelium produced were isolated and sub-cultured. Secondly, further analysis for the presence of Taxol by using chromatographic and spectrometric techniques. Illustratively, ethanol or acetone and 50% and 20% of ethanol. Then, the residues were dissolved in 5 ml of methanol and filtered. By using the internal standard, the resulting solution was subjected to the HPLC to determine the extraction efficiencies of tested solvents. Finally, filtrate was also subjected to the LC-MS – ESI using water/acetonitrile (10/90) as mobile phase to identify the authenticity of Taxol Results HPLC analysis revealed that Taxol could be quantified by UV detection using standard curve. Furthermore, the standard curve covering the concentration was linear (r2= 0.9992) and CV% ranged from 0.52 to 15.36. The peaks of fraction 5 obtained by HPLC analysis were quite similar to that of standard taxol confirming the presence of taxol. A parent ion peak of m/z 851.85 was observed in the LC–ESI–MS spectrum which was similar to paclitaxel with reported m/z of 854 [M+H] + ion. A. Alternata produced about 113.193 mg/L taxol as quantified through HPLC Conclusion we are recording for the first time the production of taxol by an endophytic fungus Alternaria Alternata. In a final word, present study results advocate that the endophytic fungus A.Alternata aids as a potential source for the production of taxol isolated from Palm branche plant

Rosthorin A inhibits non-small cell lung cancer cell growth and metastasis through repressing epithelial-mesenchymal transition via downregulating Slug.

Lung cancer always ranks first in the number of cancer deaths every year, accounting for 18.4% of total cancer deaths in 2018. Metastasis is the main cause of death in lung cancer patients. The identification of bioactive components of traditional Chinese medicine is very important for the development of novel reagents against non-small cell lung cancer (NSCLC). Rosthorin A has originated from Rabdosia rosthornii (Diels) Hara which excerpts from ‘Chinese materia medica’, and is known to have ‘clear heat phlegm’ properties in the folk. Little is known about the biological functions and mechanisms of Rosthorin A in cancer cells at present. The role of EMT in metastasis of a tumor cell is self-evident. Slug is an important EMT inducer, which is related to the development of lung cancer. Cell growth, clone assay, cell migration, cell invasion, and protein expression, and NSCLC transplanted tumor growth were performed in A549, H1299, and H1975 cells. Rosthorin A significantly inhibited the growth of NSCLC cells, it could prolong the survival of nude mice. Rosthorin A inhibited the migration and invasion of A549, H1299, and H1975 cells. Rosthorin A up-regulated E-cadherin expression level and down-regulated the expression of β-catenin, N-cadherin, vimentin, Slug, and Twist. Rosthorin A could promote the expression of E-cadherin and inhibit the development of EMT by downregulating Slug, to inhibit the development and metastasis of NSCLC cells. In summary, Rosthorin A could be used as a promising candidate for the treatment of NSCLC patients with recurrence and metastasis.

Improving Access to Vitally Important Chemotherapy Treatments in Northern Nigeria Through the African Access Initiative

PURPOSE Cancer now kills more Africans than malaria. Without intervention, the number of cancer deaths in Africa is projected to double by 2040. BIO Ventures for Global Health (BVGH) launched the African Access Initiative (AAI) to address Africa’s cancer crisis by establishing sustainable access to cancer medicines. Through AAI, BVGH and the Ahmadu Bello University Teaching Hospital (ABUTH) are piloting a first-of-its-kind program focused on improving Nigeria’s access to affordable, gold-standard cancer drugs manufactured by multinational pharmaceutical companies. METHODS BVGH, the Federal Ministry of Health, and Nigerian oncologists held a stakeholder meeting to prioritize cancers and their associated drugs. After the meeting, pharmaceutical companies were invited to submit proposals outlining the terms by which the prioritized drugs could be made available. In parallel, Nigeria’s regulatory agency, the National Agency for Food and Drug Administration and Control, was engaged to discuss expediting its review and approval of priority drugs. RESULTS Forty-one priority cancer drugs covering 8 of Nigeria’s most prevalent cancers were selected for this program. Requests for proposals were sent to 14 multinational pharmaceutical companies. Companies responded with deeply discounted access prices, the majority of which were more affordable than cancer drugs available through ABUTH’s current procurement structure. On the basis of the companies’ proposed prices, BVGH crafted a budgeting tool tailored to the cancer treatment protocols offered at ABUTH. Using this tool, ABUTH, together with 7 northern Nigerian teaching hospitals and under the leadership of Ahmadu Bello University, calculated the number of patients they could treat and drug quantities they could purchase with their current budget. The relevant funds will be placed in an externally managed escrow account to ensure oversight of the drug procurement process. BVGH is working with the pharmaceutical companies and National Agency for Food and Drug Administration and Control to hasten approval of priority drugs. CONCLUSION The AAI drug access model is not donation based. Instead, it is an innovative, demand-driven program that is uniquely positioned to ensure affordable and sustainable access to cancer drugs in Africa.

Breast cancer in younger patients in Southeast of Brazil: 10-year analysis.

e13567 Background: Breast cancer in Brazil is the most common cancer among women and is also responsible for the highest number of cancer deaths in this group. For Brazil, 66,280 new cases of breast cancer are estimated for the year 2020. This corresponds to an estimated risk of 61.61 new cases per 100 thousand women. For Espírito Santo, the estimate is 790 new cases.. Affection in women under the age of 40 is still infrequent, but it has been growing in the country with more aggressive and advanced cancer at diagnoses. It happens that in Brazil, with the publication of Ordinance 61/2015 by the Ministry of Health, the procedure became exclusive to women aged 50 to 69 years, contrary to what Federal Law 11.664 / 2008 requires, which determines the right mammography exam for all women over 40 years of age. In other words, asymptomatic women who are under 50 or over 70 years of age cannot take the exam on the public network. Methods: The data presented in this study correspond to patients diagnosed with breast cancer from 2007 to 2017 and were extracted from the database of the Hospital Cancer Registry of the Evangelical Hospital of Cachoeiro de Itapemirim (RHC / HECI) through SisRHC, a tool of management of the computerized database for Hospital Cancer Records. Results: Over the 10 years analyzed, in the south Espírito Santo region, 1,546 women started treatment for breast cancer and of these 528 were aged 49 years or less, stratified by age group: 15-24 years 9 cases (1.71%), 25-34 years 64 cases (12.13%)., 35-39 years 96 cases (18.18%), 40-44 years 156 cases (29.54%), 45-49 years. 203 cases (38.44%). A very important factor when making the diagnosis is the clinical staging (EC) of the disease, a fact that directly influences the type of treatment and the woman's survival. Of the cases analyzed, 464 had complete staging data, of these 27 (5.82%) of the cases were EC 0, EC I were 89 (19.18%), 193 (41.60%) with EC II, 122 ( 26.30%) with EC III and, finally, 33 (7.10%) in EC IV. Conclusions: In Brazil, there is a divergence between the guidance of the INCA (National Cancer Institute), an organ linked to the Ministry of Health, which recommends routine mammography after the age of 50, and the Brazilian Mastology Societies and the Brazilian College of Radiology, which indicate the exam for women over 40 years of age. In this scenario, the reduction in the supply of mammograms puts the country against the recommendations of specialists and medical societies. Mammography is a right for all Brazilian women over 40 years of age. This is the law and we need to enforce it, since the incidence of cancer cases in this age group represented one third of the cases.

2855 To Determine the Clinical Profile of Patients With Esophageal Cancers

INTRODUCTION: Cancer of the esophagus ranks twelfth among the major cancers in the number of new cases diagnosed and seventh in the number of cancer death. Its high mortality rate makes it a major concern. Numerous approaches have been described for resection of esophagus. Combined modality therapy including radiotherapy and chemotherapy has raised hope for improvement of survival with promising preliminary data.Finally, for palliation of dysphagia in those patients with advanced disease,various newer therapeutic options have been introduced like endoscopic stenting and laser ablation. Thus this study elaborates view of current literature pertaining to the disease and concludes by comparing the results of the present study with the former national and international scenario. METHODS: The one year cross sectional study was conducted at tertiary care hospital. All the patients either gender who were diagnosed as esophageal cancer were included in the study. These patients were allowed to undergo necessary investigations and treatment while the subjects excluded from study were patients who were lost to follow up and the non cooperative patients who not interested to participate in the study while the frequency / percentages (%) and means ± SD computed for study variables. RESULTS: During one year study period total fifty patients with esophageal carcinoma were explored and studied. the frequency for male and female population was 32 (64%) and 18 (36%) with mean ± sd for age of male and female individuals was 54.47 ± 5.87 and 51.75 ± 7.72 respectively. Gender male 32 (64%) and female 18 (36%), type of lesion exophytic 05 (10%), infiltrative 10 (20%), ulcerative 35 (70%), location upper third 05 (10%), middle third 30 (60%) and lower third 15 (30%). Histological type squamous cell carcinoma 36 (72%) and adenocarcinoma 14 (28%). CONCLUSION: Carcinoma esophagus is one of the most common gastrointestinal tract malignancies. It was the second most common gastrointestinal cancer in our hospital, second only to carcinoma stomach, constituting 6.2% of all malignancies. Squamous cell carcinomas accounts for the vast majority of cancers arising in high- incidence areas throughout the world.Seventy two percent of our patients had squamous cell cancer while twenty eight percent had adenocarcinoma. This reflects the difference in epidemiology and the fact that adenocarcinoma is not rising in incidence in less well- developed nations like ours compared to the West.